December 8, 2025Blood

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase II study shows high remission rates and 4-year survival in adults with ND Ph-negative B-ALL, suggesting benefits of InO addition.

The addition of inotuzumab ozogamicin led to 100% complete remission in newly diagnosed B-ALL patients.
The overall survival rate reached 91% after four years, with significant outcomes supported by next generation sequencing.
Assessment using chemoimmunotherapy with hyper-CVAD and blinatumomab shows strong efficacy without serious complications.
Findings highlight the substantial potential of InO to enhance treatment results in high-risk B-ALL patients.

Jain et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark